Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis. Bloem M, de Meza MM, van den Eertwegh AJM, Aarts MJB, et al. Br J Cancer 2025 Apr 15. doi: 10.1038/s41416-025-03021.

Read + Share

Amedeo Smart

Independent Medical Education

Bloem M, de Meza MM, van den Eertwegh AJM, Aarts MJB, et al. Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis. Br J Cancer 2025 Apr 15. doi: 10.1038/s41416-025-03021.
PMID: 40234665